Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) EBIT Margin: 2009-2025

Historic EBIT Margin for Amicus Therapeutics (FOLD) over the last 15 years, with Sep 2025 value amounting to 20.27%.

  • Amicus Therapeutics' EBIT Margin rose 497.00% to 20.27% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.48%, marking a year-over-year increase of 442.00%. This contributed to the annual value of 4.71% for FY2024, which is 2404.00% up from last year.
  • Per Amicus Therapeutics' latest filing, its EBIT Margin stood at 20.27% for Q3 2025, which was up 430.96% from -6.12% recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' EBIT Margin registered a high of 20.27% during Q3 2025, and its lowest value of -95.71% during Q1 2022.
  • Over the past 3 years, Amicus Therapeutics' median EBIT Margin value was -6.12% (recorded in 2025), while the average stood at -5.71%.
  • Its EBIT Margin has fluctuated over the past 5 years, first plummeted by 2,492bps in 2022, then soared by 5,512bps in 2023.
  • Over the past 5 years, Amicus Therapeutics' EBIT Margin (Quarterly) stood at -87.82% in 2021, then soared by 3,977bps to -48.05% in 2022, then skyrocketed by 4,484bps to -3.21% in 2023, then soared by 1,388bps to 10.67% in 2024, then spiked by 497bps to 20.27% in 2025.
  • Its EBIT Margin stands at 20.27% for Q3 2025, versus -6.12% for Q2 2025 and -6.35% for Q1 2025.